Emerald Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Emerald Advisers’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-115,983	Closed	-$7.71M	–	297
2021 Q3	$7.71M	Sell	115,983 -268	-0.2%	-$19.1K	0.28%	106
2021 Q2	$9.07M	Sell	116,251 -64,257	-36%	-$4.75M	0.33%	104
2021 Q1	$17.1M	Sell	180,508 -176,530	-49%	-$21M	0.62%	79
2020 Q4	$43.5M	Buy	357,038 +58,030	+19%	+$6.36M	1.44%	12
2020 Q3	$26.1M	Buy	299,008 +84,699	+40%	+$5.9M	1.07%	32
2020 Q2	$13.8M	Buy	214,309 +135,129	+171%	+$7.8M	0.6%	62
2020 Q1	$3.54M	Buy	+79,180	New	+$4.21M	0.2%	107

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Emerald Advisers's TPTX Position: Q4 2021 in Review

Emerald Advisers sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 115,983 shares — an estimated $7.71M sold.

Emerald Advisers first reported a position in TPTX in Q1 2020 and held it in 7 quarters. The position peaked at $43.5M in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Emerald Advisers reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Emerald Advisers sold 115,983 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $7.71M.
Emerald Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Emerald Advisers's Turning Point Therapeutics, Inc. Common Stock position peaked at $43.5M in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Emerald Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.